Candida albicans remains the main etiological agent of candidiasis, as this otherwise
normal commensal of humans is capable of causing active infection in immune-and
medically-compromised patients. The high morbidity and mortality rates associated with
candidiasis, coupled with the emergence of drug resistance demand the development of
novel therapeutic strategies. However, there is a paucity of selective targets that can be
exploited in the development of new antifungals. Contrary to conventional antibiotics that kill …